Provided by Tiger Trade Technology Pte. Ltd.

NanoViricides

1.00
-0.0100-0.99%
Volume:19.72K
Turnover:19.77K
Market Cap:21.57M
PE:-2.08
High:1.01
Open:1.00
Low:0.9901
Close:1.01
52wk High:2.23
52wk Low:0.8500
Shares:21.57M
Float Shares:20.97M
Volume Ratio:0.36
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4813
EPS(LYR):-0.6263
ROE:-77.53%
ROA:-44.02%
PB:1.95
PE(LYR):-1.60

Loading ...

NanoViricides Announces NV-387 Shows Potent Anti-Measles Activity in Phase I Trial

Reuters
·
Oct 29, 2025

NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies

Reuters
·
Oct 22, 2025

BRIEF-Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal Model

Reuters
·
Oct 21, 2025

NanoViricides: Nv-387 Has Already Completed Phase I Clinical Trial in Healthy Subjects With No Reported Adverse Events

THOMSON REUTERS
·
Oct 20, 2025

NanoViricides: Clinical Lead Drug Nv-387 Has Shown Strong Activity Against Measles Virus in a Humanized Animal Model

THOMSON REUTERS
·
Oct 20, 2025

NanoViricides: Nv-387 Can NOW Be Made Available for Emergency Use Application in Measles Patients to Respond to Spreading Measles Outbreaks

THOMSON REUTERS
·
Oct 20, 2025

NanoViricides Announces Strong Measles Drug Results and Emergency Use Availability

Reuters
·
Oct 20, 2025

NanoViricides Inc. Announces Date for Upcoming Annual Meeting of Stockholders

Reuters
·
Oct 08, 2025

NanoViricides Inc. Announces New Compensation Agreements, Extends President Dr. Anil Diwan’s Contract with $400,000 Salary and Equity Incentives

Reuters
·
Oct 02, 2025

Nanoviricides Q4 EPS $(0.13) Up From $(0.19) YoY

Benzinga
·
Sep 30, 2025

NanoViricides Reports No Revenue for Fiscal Year Ended June 30, 2025; Net Loss Continues as R&D Expenses Rise by $112,000

Reuters
·
Sep 30, 2025

NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPOX Disease

Reuters
·
Sep 09, 2025